Intellectual Property Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial
Company Manufacturing Leads Selected as Thought Leaders to Discuss Advances in Lipid Nanoparticle Delivery Systems
Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors
Company achieves major milestones in clinical development programs in 2022 Patient treatment in Acclaim-2 clinical trial commences